Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

CC-930 (Tanzisertib)

Catalog No: tcsc1544

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Specifications

CAS No:
899805-25-5

Formula:
$C_{21}H_{23}F_3N_6O_2$

Pathway:
MAPK/ERK Pathway

Target:
JNK

Purity / Grade:
>98%

Solubility:
DMSO : ≥ 33 mg/mL (73.59 mM)

Alternative Names:
CC-930

Observed Molecular Weight:
448.44

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Product Description

Tanzisertib (CC-930) is a potent **JNK1/2/3** inhibitor with **IC_{50}**s of 61/7/6 nM, respectively.

IC50 & Target: IC50: 61 nM (JNK1), 7 nM (JNK2), 6 nM (JNK3)[1]

In Vitro: Tanzisertib (CC-930) inhibits the formation of phospho-cJun in human PBMC stimulated by phorbol-12-myristate-13-acetate and phytohemeagglutinin (IC_{50}=1 μM)[1]. Tanzisertib (CC-930) (1-2 μM) substantially reduces hepatocyte apoptosis and necrosis, abrogates apoptosis and necrosis in FC-loaded WT hepatocytes[2]. Tanzisertib (CC-930) blocks the JNK pathway that is activated by pro-fibrotic cytokines in systemic sclerosis[3].

In Vivo: Tanzisertib (CC-930) (10 and 30 mg/kg, p.o.) inhibits the production of TNFa by 23% and 77% in the acute rat LPS-induced TNFa production PK-PD model[1]. Tanzisertib (CC-930) (150 mg/kg) prevents the development of fibrosis in different models, but can also induce the regression of pre-existing fibrosis[3].